TCL1-002 cell line
Invented by Dr Dimitar Efremov
Invented at International Centre For Genetic Engineering And Biotechnology (ICGEB)
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 154648 |
| Antigen/Gene or Protein Targets | e.g. chronic lymphocytic leukemia |
| Parental Line | Eµ-TCL1 |
| Host | Mouse |
| Tissue | Lymphatic Tissue |
| Disease Keywords | Chronic lymphocytic leukemia, CLL |
| Model | Cancer Model |
| Relevance | The proliferation and survival of chronic lymphocytic leukemia (CLL) B-cells is regulated by intracellular signaling pathways which are activated by various stimuli such as antigenic stimuli propagaged through the B-cell receptor (BCR). For this reason inhibition of antigen-dependent BCR signalling can be considered a promising therapeutic approach in CLL. Some studies have shown that sustained engagement of the BCR induces a powerful antiapoptotic program in CLL cells. Transduction of the prosurvival BCR signal was shown to involve the recruitment and activation of several kinases, including Syk. Increased basal activity of Syk kinase has been described in CLL and several other B-cell malignancies and shown to contribute to the increased apoptosis resistance of the malignant lymphocytes. Interestingly, the antiapoptotic program in CLL cells caused by sustained BCR engagement can be completely abrogated with selective inhibition of Syk kinase, suggesting that the Syk kinase could be a potential target for therapeutic intervention. This Eµ-TCL1-002 cell line (a transgenic mouse model of chronic lymphocytic leukemia) strongly expresses Syk kinase. |
| Production Details | Established from an Eµ-TCL1 transgenic colony which had a B6/C3H background. Adoptive-transfer experiments with this leukemia was done in B6/C3H F1 recipients (6- to 8-week-old female mice). For adoptive transfer, 1.5 x 10^7 TCL1 leukemia cells were thawed, resuspended in 500 µL of phosphate-buffered saline (PBS), and injected intraperitoneally into the syngeneic recipients. Mice were followed for leukemia development and were euthanized when they developed signs and symptoms of a moribund state, such as lethargy, aversion to activity, lack of sustained purposeful response to gentle stimuli, shallow or labored breathing, and other disabling symptoms. |
| Conditional | No |
| Research Area | Apoptosis and Programmed Cell Death, Cancer, Cell Signaling & Signal Transduction |
| Recommended Growing Conditions | Must be propagated in vivo. |
| Notes | TCL1-002 murine leukaemia cells are splenic B cells which express high levels of phosphorylated Syk. They have low viability in vitro. |
References: 1 entry
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signalling.
Add a reference
References: 1 entry
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signalling.
Add a reference
Inventor Information
Inventors
|
Dr Dimitar Efremov |
